ESMO 2022 | Adjuvant endocrine therapy for breast cancer: optimal durations and regimens

Evandro De Azambuja, MD, PhD, Jules Bordet Institute, Brussels, Belgium, explores the role of adjuvant endocrine therapy in breast cancer. Dr De Azambuja discusses the optimal duration of adjuvant endocrine therapy in order to avoid relapse, and compares the best drugs for different patients, as well as discussing two tools for assessing the risk of relapse: the Breast Cancer Index and the CTS5 calculation. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.